Side-by-side comparison of AI visibility scores, market position, and capabilities
AI antibody design platform targeting undruggable GPCRs and ion channels; $37M raised with $550M+ in AstraZeneca, BMS, and Takeda partnership milestones led by Radical Ventures.
Nabla Bio is a Harvard spinout biotech company using AI-driven generative protein design to develop antibodies against multipass membrane proteins — a class of drug targets including GPCRs (G protein-coupled receptors), ion channels, and transporters that are implicated in numerous diseases but have been historically undruggable with antibody therapies due to their complex 3D structure embedded in the cell membrane. A Y Combinator graduate, Nabla Bio raised $37 million total including a $26 million Series A led by Radical Ventures, and secured strategic collaborations with AstraZeneca, Bristol Myers Squibb, and Takeda worth $550 million+ in upfront and milestone payments plus royalties.
Kindful, nonprofit donor management/CRM platform (acquired by Bloomerang 2020), 1,000+ nonprofit customers, cloud-based fundraising software, online donation forms, donor analytics, email marketing, integrated with QuickBooks/Mailchimp, now part of Bloomerang suite
Kindful is a donor management and fundraising platform designed for nonprofit organizations to manage relationships, track donations, and execute fundraising campaigns. The company serves small to mid-sized nonprofits who need affordable, user-friendly software to organize donor data, process contributions, and measure fundraising effectiveness. Kindful provides tools for online giving, email marketing, event management, donor segmentation, and reporting that help nonprofits build stronger relationships with supporters, streamline fundraising operations, and increase donations while reducing administrative burden.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.